Peer Review reports
From: The landscape of immune checkpoint inhibitor therapy in advanced lung cancer
| Original Submission | ||
|---|---|---|
| 19 Apr 2021 | Submitted | Original manuscript |
| 13 May 2021 | Reviewed | Reviewer Report |
| 25 May 2021 | Reviewed | Reviewer Report |
| 27 May 2021 | Reviewed | Reviewer Report |
| 20 Jun 2021 | Author responded | Author comments - Chengdi Wang |
| Resubmission - Version 2 | ||
| 20 Jun 2021 | Submitted | Manuscript version 2 |
| 26 Jun 2021 | Reviewed | Reviewer Report |
| 10 Jul 2021 | Author responded | Author comments - Chengdi Wang |
| Resubmission - Version 3 | ||
| 10 Jul 2021 | Submitted | Manuscript version 3 |
| 28 Jul 2021 | Author responded | Author comments - Chengdi Wang |
| Resubmission - Version 4 | ||
| 28 Jul 2021 | Submitted | Manuscript version 4 |
| Publishing | ||
| 3 Aug 2021 | Editorially accepted | |
| 28 Aug 2021 | Article published | 10.1186/s12885-021-08662-2 |
You can find further information about peer review here.